MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab,…
The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019, equivalent to €28.8 billion at 2025 prices, according to a new study published in Movement Disorders.
Gilead Sciences' HIV treatment arsenal is getting bigger. The leading drugmaker in the four-decade epidemic gained another FDA stamp of approval on Thursday. This time, Gilead will market ...
The medical community is trying many approaches to help push back against the advance of Alzheimer's and dementia. One leading institution is taking a different and unconventional approach to…
